AU2023216366A1 - Methods of weight loss and preserving skeletal muscle mass - Google Patents

Methods of weight loss and preserving skeletal muscle mass Download PDF

Info

Publication number
AU2023216366A1
AU2023216366A1 AU2023216366A AU2023216366A AU2023216366A1 AU 2023216366 A1 AU2023216366 A1 AU 2023216366A1 AU 2023216366 A AU2023216366 A AU 2023216366A AU 2023216366 A AU2023216366 A AU 2023216366A AU 2023216366 A1 AU2023216366 A1 AU 2023216366A1
Authority
AU
Australia
Prior art keywords
subject
reduction
fat
per day
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023216366A
Other languages
English (en)
Inventor
Diane JORKASKY
Shaharyar Khan
Francisco PORTELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rivus Pharmaceuticals Inc
Original Assignee
Rivus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rivus Pharmaceuticals Inc filed Critical Rivus Pharmaceuticals Inc
Publication of AU2023216366A1 publication Critical patent/AU2023216366A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2023216366A 2022-02-07 2023-02-06 Methods of weight loss and preserving skeletal muscle mass Pending AU2023216366A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307506P 2022-02-07 2022-02-07
US63/307,506 2022-02-07
US202263382456P 2022-11-04 2022-11-04
US63/382,456 2022-11-04
PCT/US2023/062077 WO2023150767A1 (en) 2022-02-07 2023-02-06 Methods of weight loss and preserving skeletal muscle mass

Publications (1)

Publication Number Publication Date
AU2023216366A1 true AU2023216366A1 (en) 2024-08-15

Family

ID=85556813

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023216366A Pending AU2023216366A1 (en) 2022-02-07 2023-02-06 Methods of weight loss and preserving skeletal muscle mass

Country Status (12)

Country Link
US (1) US20250134864A1 (https=)
EP (1) EP4475841A1 (https=)
JP (1) JP2025505187A (https=)
KR (1) KR20240146052A (https=)
AU (1) AU2023216366A1 (https=)
CA (1) CA3243640A1 (https=)
CL (1) CL2024002341A1 (https=)
GE (1) GEAP202416578A (https=)
IL (1) IL314684A (https=)
JO (1) JOP20240177A1 (https=)
MX (1) MX2024009646A (https=)
WO (1) WO2023150767A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199516A1 (en) * 2024-03-22 2025-09-25 Board Of Regents, The University Of Texas System Compositions and methods for preserving or increasing lean muscle mass

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3565806T (pt) 2017-01-06 2022-05-19 Rivus Pharmaceuticals Inc Novos derivados de fenilo

Also Published As

Publication number Publication date
US20250134864A1 (en) 2025-05-01
CA3243640A1 (en) 2023-08-10
JOP20240177A1 (ar) 2024-08-04
GEAP202416578A (en) 2024-11-11
WO2023150767A1 (en) 2023-08-10
EP4475841A1 (en) 2024-12-18
IL314684A (en) 2024-10-01
CL2024002341A1 (es) 2025-01-17
KR20240146052A (ko) 2024-10-07
MX2024009646A (es) 2024-11-08
JP2025505187A (ja) 2025-02-21

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
KR20240162094A (ko) 미르다메티닙 치료
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
TW202114671A (zh) 包含fxr促效劑之治療
US20250134864A1 (en) Methods of weight loss and preserving skeletal muscle mass
TW202313010A (zh) 治療粒線體相關病症之方法
WO2009015561A1 (en) The use of leonurine and compositions thereof
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
CN111386115A (zh) 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
US20250134865A1 (en) Methods of weight loss in a subject with elevated hba1c
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法
KR20250145673A (ko) 통증 완화에 유용한 요법 및 조성물
CN118922187A (zh) 体重减轻和保持骨骼肌量的方法
CN112107581A (zh) 式i化合物在制备治疗肥胖及相关病症的药中的用途
CN117881399A (zh) 治疗粒线体相关病症的方法
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
WO2026037397A1 (zh) Glp-1类似物的医药用途
CN121969358A (zh) 选择性雄激素受体调节剂（sarm）化合物在长期体重管理中的用途
CN110038014A (zh) 血红素在改善夜间尿频的药物、食品及保健食品中的应用
JP2018108969A (ja) リンパ浮腫の治療薬